Scale-up of Kenya’s national HIV viral load program: Findings and lessons learned

Objectives Kenya is one of the first African countries to scale up a national HIV viral load monitoring program. We sought to assess program scale up using the national database and identify areas for systems strengthening. Methods Data from January 2012 to March 2016 were extracted from Kenya’s national viral load database. Characteristics of 1,108,356 tests were assessed over time, including reason for testing, turnaround times, test results, treatment regimens, and socio-demographic information. Results The number of facilities offering viral load testing increased to ~2,000 with >40,000 tests being conducted per month by 2016. By March 2016, most (84.2%) tests were conducted for routine monitoring purposes and the turnaround time from facility-level sample collection to result dispatch from the lab was 21(24) [median (IQR)] days. Although the proportions of repeat viral load tests increased over time, the volumes were lower than expected. Elevated viral load was much more common in pediatric and adolescent patients (0-<3 years: 43.1%, 3-<10 years: 34.5%, 10-<20 years: 36.6%) than in adults (30-<60 years: 13.3%; p<0.001). Conclusions Coverage of viral load testing dramatically increased in Kenya to >50% of patients on antiretroviral therapy (ART) by early 2016 and represents a relatively efficient laboratory system. However, strengthening of patient tracking mechanisms and viral load result utilization may be necessary to further improve the system. Additional focus is needed on paediatric/adolescent patients to improve viral suppression in these groups. Kenya’s national viral load database has demonstrated its usefulness in assessing laboratory programs, tracking trends in patient characteristics, monitoring scale-up of new policies and programs, and identifying problem areas for further investigation.

[1]  R. Wanyenze,et al.  Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015 , 2017, BMC Infectious Diseases.

[2]  J. Nkengasong,et al.  Specimen origin, type and testing laboratory are linked to longer turnaround times for HIV viral load testing in Malawi , 2017, PloS one.

[3]  J. Overbaugh,et al.  Differences in virologic and immunologic response to antiretroviral therapy among HIV-1-infected infants and children , 2016, AIDS.

[4]  J. Baeten,et al.  HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy , 2016, Journal of acquired immune deficiency syndromes.

[5]  Anthony K. Waruru,et al.  Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey , 2016, PloS one.

[6]  S. Gregson,et al.  Can Schools Support HIV/AIDS-Affected Children? Exploring the ‘Ethic of Care’ amongst Rural Zimbabwean Teachers , 2016, PLoS ONE.

[7]  K. Bonner,et al.  Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Gregson,et al.  It's harder for boys? Children's representations of their HIV/AIDS-affected peers in Zimbabwe , 2015, AIDS care.

[9]  L. Cluver,et al.  Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review , 2015, AIDS care.

[10]  R. Kosgei,et al.  Factors Associated with Virological Failure and Suppression after Enhanced Adherence Counselling, in Children, Adolescents and Adults on Antiretroviral Therapy for HIV in Swaziland , 2015, PloS one.

[11]  P. Lall,et al.  Review: An urgent need for research on factors impacting adherence to and retention in care among HIV-positive youth and adolescents from key populations , 2015, Journal of the International AIDS Society.

[12]  Patrick A Ryscavage,et al.  Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review , 2015, Journal of the International AIDS Society.

[13]  P. Goulder,et al.  Immunity to HIV in Early Life , 2014, Front. Immunol..

[14]  L. Muhe,et al.  Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. , 2014, The Cochrane database of systematic reviews.

[15]  S. Gregson,et al.  Children’s representations of school support for HIV-affected peers in rural Zimbabwe , 2014, BMC Public Health.

[16]  U. Liebert,et al.  Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children , 2014, BMC Infectious Diseases.

[17]  B. Eley,et al.  Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: A multicentre cohort study from South Africa , 2014, AIDS care.

[18]  C. Hamilton,et al.  Differences Between HIV-Infected Men and Women in Antiretroviral Therapy Outcomes — Six African Countries, 2004–2012 , 2013, MMWR. Morbidity and mortality weekly report.

[19]  S. Urien,et al.  Evaluation of nevirapine dosing recommendations in HIV-infected children. , 2013, British journal of clinical pharmacology.

[20]  J. Elliott,et al.  Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. , 2013, Bulletin of the World Health Organization.

[21]  R. Greil,et al.  Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals , 2009, Antiviral therapy.

[22]  Ross J. Harris,et al.  Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. , 2009, International journal of epidemiology.

[23]  A. Walker,et al.  Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study , 2006, BMJ : British Medical Journal.

[24]  A. Geretti,et al.  Comparative Evaluation of the Performance of the Abbott Real-Time Human Immunodeficiency Virus Type 1 (HIV-1) Assay for Measurement of HIV-1 Plasma Viral Load following Automated Specimen Preparation , 2006, Journal of Clinical Microbiology.

[25]  J. Ioannidis,et al.  Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. , 1998, The New England journal of medicine.

[26]  L. Kalish,et al.  Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.

[27]  Melbourne Victoria,et al.  A Ministry of Health , 1917, Nature.